CheckMate 7DX
03 Dec 2020
Trial Summary
The purpose of this study is to test the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation
Acronym:
CheckMate 7DX
ACTRN/NCT /ethics:
NCT04100018
Scientific title:
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Sponsor / Cooperative group:
Bristol-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2019-12-06 |
| Anticipated End Date | 2024-07-06 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Vineet Kwatra |
| Recruitment Status | Recruiting |